Baseline circulating tumor cell (CTC) count as a prognostic marker of PSA response and progression in metastatic castrate sensitive prostate cancer (mCSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide.

被引：0

作者：

Goldkorn, Amir

Tangen, Catherine

Plets, Melissa

Morrison, Gareth

Cunha, Alexander

Xu, Tong

Pinski, Jacek K.

Ingles, Sue A.

Triche, Timothy

MacVicar, Gary R.

Vaena, Daniel A.

Crispino, Anthony W.

McConkey, David James

Lara, Primo

Hussain, Maha H. A.

Quinn, David, I

Vogelzang, Nicholas J.

Thompson, Ian Murchie

Agarwal, Neeraj

机构：

[1] Univ Southern Calif, Keck Sch Med, Dept Med, Div Med Oncol, Los Angeles, CA 90007 USA

[2] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA

[3] Fred Hutchinson Canc Res Ctr, SWOG Stat Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[4] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA

[5] Univ Southern Calif, Los Angeles, CA 90007 USA

[6] USC Keck Sch Med Norris Comprehens Canc Ctr, Los Angeles, CA USA

[7] USC Childrens Hosp Los Angeles, Los Angeles, CA USA

[8] Illinois CancerCare PC, Peoria, IL USA

[9] Univ Iowa Hosp & Clin, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA

[10] UsTOO Las Vegas, Las Vegas, NV USA

[11] Johns Hopkins Greenberg Bladder Canc Inst, Baltimore, MD USA

[12] Univ Calif, Sacramento, CA USA

[13] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA

[14] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA

[15] Comprehens Canc Ctr Nevada, Las Vegas, NV USA

[16] Christus Santa Rosa Hosp Med Ctr, San Antonio, TX USA

[17] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

基金：

美国国家卫生研究院;

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

5506

引用

页数：2

共 11 条

[1] Baseline circulating tumor cell (CTC) count as a prognostic marker of overall survival (OS) in metastatic hormone sensitive prostate cancer (mHSPC): Results from SWOG S1216, a phase III randomized trial of androgen deprivation plus orteronel (cyp17 inhibitor) or bicalutamide
Goldkorn, Amir
Tangen, Catherine
Plets, Melissa
Bsteh, Daniel
Xu, Tong
Pinski, Jacek K.
Ingles, Sue
Triche, Timothy Junius
MacVicar, Gary R.
Vaena, Daniel A.
Crispino, Anthony W.
McConkey, David James
Lara, Primo N.
Hussain, Maha H. A.
Quinn, David I.
Dorff, Tanya B.
Thompson, Ian
Agarwal, Neeraj
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[2] Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216)
Goldkorn, Amir
Tangen, Catherine
Plets, Melissa
Morrison, Gareth J.
Cunha, Alexander
Xu, Tong
Pinski, Jacek K.
Ingles, Sue A.
Triche, Timothy
Harzstark, Andrea L.
Kohli, Manish
MacVicar, Gary R.
Vaena, Daniel A.
Crispino, Anthony W.
McConkey, David J.
Lara, Primo N., Jr.
Hussain, Maha H. A.
Quinn, David I.
Vogelzang, Nicholas J.
Thompson, Ian Murchie, Jr.
Agarwal, Neeraj
CLINICAL CANCER RESEARCH, 2021, 27 (07) : 1967 - 1973
[3] Bone biomarkers and subsequent survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): Results from the phase III SWOG S1216 trial of androgen deprivation plus /- orteronel
Lara, Primo N.
Mayerson, Edward
Gertz, Erik
Tangen, Catherine
Goldkorn, Amir
Van Loan, Marta
Hussain, Maha H. A.
Gupta, Shilpa
Zhang, Jingsong
Parikh, Mamta
Twardowski, Przemyslaw
Quinn, David I.
LeBlanc, Michael Leo
Thompson, Ian M.
Agarwal, Neeraj
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] Bone metabolism biomarkers (BMB) in hormone sensitive prostate cancer (HSPC): Results from SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) plus /- orteronel
Lara, P. N.
Mayerson, E.
Gertz, E.
Tangen, C.
Goldkorn, A.
van Loan, M.
Hussain, M.
Gupta, S.
Zhang, J.
Twardowski, P.
Quinn, D. I.
Vogelzang, N. J.
Thompson, I.
Agarwal, N.
ANNALS OF ONCOLOGY, 2018, 29 : 275 - U475
[5] Three- and Seven-month Prostate-specific Antigen Levels as Prognostic Markers for Overall Survival in Metastatic Hormone- sensitive Prostate Cancer: Results from SWOG S1216, a Phase 3 Randomized Trial of Androgen Deprivation Plus Orteronel or Bicalutamide
Parikh, Mamta
Tangen, Catherine
Hussain, Maha H. A.
Gupta, Shilpa
Callis, Sam
Jo, Yeonjung
Harzstark, Andrea
Paller, Channing J.
George, Saby
Zibelman, Matthew R.
Cheng, Heather H.
Maughan, Benjamin L.
Zhang, Jingsong
Pachynski, Russell K.
Bryce, Alan H.
Lin, Daniel W.
Quinn, David I.
Lerner, Seth P.
Thompson, Ian M.
Dorff, Tanya B.
Lara, Primo N.
Agarwal, Neeraj
EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (05): : 1097 - 1104
[6] Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel
Lara, Primo N.
Mayerson, Edward
Gertz, Erik
Tangen, Catherine
Goldkorn, Amir
van Loan, Marta
Hussain, Maha
Gupta, Shilpa
Zhang, Jingsong
Parikh, Mamta
Twardowski, Przemyslaw
Quinn, David I.
Leblanc, Michael
Vogelzang, Nicholas J.
Thompson, Ian
Agarwal, Neeraj
EUROPEAN UROLOGY, 2024, 85 (02) : 171 - 176
[7] Markers of bone metabolism and overall survival in men with bone-metastatic hormone sensitive prostate cancer (HSPC): A subset analysis of SWOG S1216, a phase III trial of androgen deprivation with or without orteronel
Lara Jr, Primo N.
Mayerson, Edward
Gertz, Erik
Tangen, Catherine
Goldkorn, Amir
van Loan, Marta
Hussain, Maha
Gupta, Shilpa
Zhang, Jingsong
Parikh, Mamta
Twardowski, Przemyslaw
Quinn, David I.
LeBlanc, Michael
Thompson, Ian
Agarwal, Neeraj
PROSTATE CANCER AND PROSTATIC DISEASES, 2024, 27 (03) : 566 - 570
[8] SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (Aft) plus TAK-700 with ADT plus bicalutamide in patients with newly diagnosed metastatic hormone-sensitive prostate cancer (HSPC) (NCT01809691).
Agarwal, Neeraj
Tangen, Catherine M.
Hussain, Mahn
Lara, Primo
Higano, Celestia S.
Vaena, Daniel A.
MacVicar, Gary R.
Li, Hongli
Crispino, Tony
Quinn, David I.
Vogolzang, Nicholas J.
Thompson, Ian Murchie
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[9] Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone-sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel.
Lara, Primo
Mayerson, Edward
Gertz, Erik
Tangen, Catherine
Goldkorn, Amir
Van Loan, Marta
Hussain, Maha H. A.
Gupta, Shilpa
Zhang, Jingsong
Twardowski, Przemyslaw
Quinn, David, I
Vogelzang, Nicholas J.
Thompson, Ian Murchie
Agarwal, Neeraj
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).
Agarwal, Neeraj
Tangen, Catherine
Hussain, Maha H. A.
Gupta, Shilpa
Plets, Melissa
Lara, Primo
Harzstark, Andrea
Twardowski, Przemyslaw
Paller, Channing Judith
Zylla, Dylan M.
Zibelman, Matthew R.
Levine, Ellis Glenn
Roth, Bruce J.
Goldkorn, Amir
Vaena, Daniel A.
Kohli, Manish
Crispino, Tony
Vogelzang, Nicholas J.
Thompson, Ian Murchie
Quinn, David I.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 →